Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Tempest Therapeutics files to sell 6.36M shares of common stock for holders  18:15
05/16/22
05/16
18:15
05/16/22
18:15
TPST

Tempest Therapeutics

$3.02 /

+0.135 (+4.68%)

 
ShowHide Related Items >><<
TPST Tempest Therapeutics
$3.02 /

+0.135 (+4.68%)

TPST Tempest Therapeutics
$3.02 /

+0.135 (+4.68%)

05/13/22 Piper Sandler
Tempest Therapeutics price target lowered to $10 from $20 at Piper Sandler
05/13/22 H.C. Wainwright
Tempest Therapeutics price target lowered to $35 from $51 at H.C. Wainwright
04/27/22 Piper Sandler
Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20
10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
TPST Tempest Therapeutics
$3.02 /

+0.135 (+4.68%)

Over a week ago
Recommendations
Tempest Therapeutics price target lowered to $10 from $20 at Piper Sandler » 11:03
05/13/22
05/13
11:03
05/13/22
11:03
TPST

Tempest Therapeutics

$2.86 /

+0.13 (+4.76%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Tempest Therapeutics to $10 from $20 due to higher discount rates to reflect current market conditions and keeps an Overweight rating on the shares following the company's Q1 update. Tempest will present full Phase I data on TPST-1120 monotherapy and in combination with Opdivo in an oral presentation at the upcoming ASCO meeting and will also present Phase I TPST-1495 monotherapy and Keytruda combination data later this year, Tenthoff noted.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$2.86 /

+0.13 (+4.76%)

TPST Tempest Therapeutics
$2.86 /

+0.13 (+4.76%)

05/13/22 H.C. Wainwright
Tempest Therapeutics price target lowered to $35 from $51 at H.C. Wainwright
04/27/22 Piper Sandler
Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20
10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
TPST Tempest Therapeutics
$2.86 /

+0.13 (+4.76%)

Recommendations
Tempest Therapeutics price target lowered to $35 from $51 at H.C. Wainwright » 10:07
05/13/22
05/13
10:07
05/13/22
10:07
TPST

Tempest Therapeutics

$2.72 /

-0.01 (-0.37%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Tempest Therapeutics to $35 from $51 and keeps a Buy rating on the shares following the Q1 results. Throughout the first quarter, the company continued to make further progress on each of its three programs, Pantginis tells investors in a research note.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$2.72 /

-0.01 (-0.37%)

TPST Tempest Therapeutics
$2.72 /

-0.01 (-0.37%)

04/27/22 Piper Sandler
Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20
10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
TPST Tempest Therapeutics
$2.72 /

-0.01 (-0.37%)

Earnings
Tempest Therapeutics reports Q1 EPS ($1.18), consensus ($1.12) » 08:02
05/13/22
05/13
08:02
05/13/22
08:02
TPST

Tempest Therapeutics

$2.73 /

-0.09 (-3.19%)

"The team continued…

"The team continued to execute well throughout the first quarter of this year, enabling us to present the first clinical data from a Tempest program at the ASCO Annual Meeting in June," said Stephen R. Brady, CEO of Tempest. "We look forward to the upcoming oral presentation, which will highlight the clinical profile and responses observed in the monotherapy and combination Phase 1 study of TPST-1120, our novel PPARa antagonist."

ShowHide Related Items >><<
TPST Tempest Therapeutics
$2.73 /

-0.09 (-3.19%)

TPST Tempest Therapeutics
$2.73 /

-0.09 (-3.19%)

04/27/22 Piper Sandler
Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20
10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
Recommendations
Piper Sandler keeps Overweight on Tempest Therapeutics, lowers target to $20 » 13:07
04/27/22
04/27
13:07
04/27/22
13:07
TPST

Tempest Therapeutics

$3.06 /

+0.64 (+26.45%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Tempest Therapeutics to $20 from $23 to account for dilution from the PIPE, while keeping an Overweight rating on the shares. The analyst notes that Tempest conducted a $15 million PIPE issuing 3.15 million shares and 3.21 million pre-funded warrants at $2.36, bringing pro forma cash to about $67 million. Tempest is expected to present full Phase I data on PPARalpha antagonist TPST-1120 monotherapy and in combination with Opdivo in an oral presentation at ASCO, Tenthoff adds.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$3.06 /

+0.64 (+26.45%)

TPST Tempest Therapeutics
$3.06 /

+0.64 (+26.45%)

10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
07/13/21 H.C. Wainwright
Tempest Therapeutics initiated with a Buy at H.C. Wainwright
TPST Tempest Therapeutics
$3.06 /

+0.64 (+26.45%)

Hot Stocks
Tempest Therapeutics announces private placement financing of $15M » 08:09
04/27/22
04/27
08:09
04/27/22
08:09
TPST

Tempest Therapeutics

$2.36 /

-0.215 (-8.35%)

Tempest Therapeutics…

Tempest Therapeutics announced a $15 million private investment in public equity financing from the sale of 3,149,912 shares of its common stock at a price per share of $2.36 and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,206,020 shares of its common stock at price per pre-funded warrant of $2.359 to EcoR1 Capital, LLC and Versant Venture Capital. Gross proceeds from the PIPE financings total approximately $15.0 million, before deducting offering expenses. The closing of the PIPE financing is subject to customary closing conditions and is expected to close by April 29, 2022.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$2.36 /

-0.215 (-8.35%)

TPST Tempest Therapeutics
$2.36 /

-0.215 (-8.35%)

10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
07/13/21 H.C. Wainwright
Tempest Therapeutics initiated with a Buy at H.C. Wainwright
TPST Tempest Therapeutics
$2.36 /

-0.215 (-8.35%)

Conference/Events
Tempest Therapeutics management to meet virtually with William Blair » 04:55
04/27/22
04/27
04:55
04/27/22
04:55
TPST

Tempest Therapeutics

$2.36 /

-0.215 (-8.35%)

Virtual Meetings with…

Virtual Meetings with management to be held on April 26-27 hosted by William Blair.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$2.36 /

-0.215 (-8.35%)

TPST Tempest Therapeutics
$2.36 /

-0.215 (-8.35%)

10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
07/13/21 H.C. Wainwright
Tempest Therapeutics initiated with a Buy at H.C. Wainwright
TPST Tempest Therapeutics
$2.36 /

-0.215 (-8.35%)

Conference/Events
Tempest Therapeutics management to meet virtually with William Blair » 04:55
04/26/22
04/26
04:55
04/26/22
04:55
TPST

Tempest Therapeutics

$2.58 /

+0.16 (+6.63%)

Virtual Meetings with…

Virtual Meetings with management to be held on April 26-27 hosted by William Blair.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$2.58 /

+0.16 (+6.63%)

TPST Tempest Therapeutics
$2.58 /

+0.16 (+6.63%)

10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
07/13/21 H.C. Wainwright
Tempest Therapeutics initiated with a Buy at H.C. Wainwright
TPST Tempest Therapeutics
$2.58 /

+0.16 (+6.63%)

Conference/Events
Tempest Therapeutics management to meet virtually with William Blair » 15:18
04/21/22
04/21
15:18
04/21/22
15:18
TPST

Tempest Therapeutics

$2.67 /

-0.02 (-0.74%)

Virtual Meetings with…

Virtual Meetings with management to be held on April 26-27 hosted by William Blair.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$2.67 /

-0.02 (-0.74%)

TPST Tempest Therapeutics
$2.67 /

-0.02 (-0.74%)

10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
07/13/21 H.C. Wainwright
Tempest Therapeutics initiated with a Buy at H.C. Wainwright
TPST Tempest Therapeutics
$2.67 /

-0.02 (-0.74%)

Over a month ago
Hot Stocks
Tempest Therapeutics reports preclinical data on TREX1, TPST-1495 programs » 13:29
04/08/22
04/08
13:29
04/08/22
13:29
TPST

Tempest Therapeutics

$3.83 /

+0.07 (+1.86%)

Tempest Therapeutics…

Tempest Therapeutics announced the presentation of two poster presentations at the 2022 American Association for Cancer Research Annual Meeting reporting new preclinical data that support the company's preclinical TREX1 and clinical TPST-1495 programs. The first presentation reports on new preclinical data that support TPST-1495, a novel agent designed to specifically block the cancer-promoting EP2 and EP4 prostaglandin E2 receptors, further differentiating TPST-1495 from other approaches targeting the PGE2 pathway. The second presentation reports on proprietary inhibitors of TREX1, a cytosolic DNA exonuclease that inhibits activation of cGAS/STING in tumor and immune cells. #1333: "Dual Blockade of the EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for Drugging the Prostaglandin Pathway": In vivo data demonstrated that monotherapy TPST-1495 significantly reduced tumor growth in mice via both T cell-independent and T-cell dependent mechanisms. The anti-tumor effect correlated with direct anti-proliferative effects on tumors in addition to increased tumor infiltration by NK cells, CD8+ T cells, AH1-specific CD8+ T cells, and other anti-tumor myeloid and adaptive immune cell populations. Demonstrating its differentiated potency, therapy with TPST-1495 resulted in a significant survival advantage as compared to therapy with single EP2 or EP4 antagonists, or the NSAID celecoxib, in the APCmin/+ spontaneous colorectal cancer tumor mouse model. Additional data demonstrated that the administration of TPST-1495 resulted in near-complete restoration of immune function in human immune cell assays, reversing prostaglandin-mediated suppression of lipopolysaccharide stimulation-induced TNF-alpha production, even in the presence of elevated PGE2 concentrations in which single EP4 or EP2 inhibitors were not effective. #2075: "Systemic Small Molecule TREX1 Inhibitors to Selectively Activate STING in the TME of Metastatic Disease": The inaugural presentation for the TREX1 program summarized the approach to develop selective TREX1 inhibitor small molecules with picomolar potency. TREX1 inhibitors were profiled in various human and mouse cell-based assays, demonstrating that inhibition of TREX1 nuclease activity resulted in increased cGAS/STING pathway signaling and production of a reporter or interferon beta. The anti-tumor activity of TREX1 inhibitors was evaluated in mice given sub-therapeutic doses of doxorubicin to effect double-stranded breaks in tumor cell DNA and induce the production of TREX1, resulting in significant anti-tumor efficacy and survival.

ShowHide Related Items >><<
TPST Tempest Therapeutics
$3.83 /

+0.07 (+1.86%)

TPST Tempest Therapeutics
$3.83 /

+0.07 (+1.86%)

10/21/21 William Blair
William Blair starts Tempest Therapeutics with buy on oncology assets
10/21/21 William Blair
Tempest Therapeutics initiated with an Outperform at William Blair
07/13/21
Fly Intel: Top five analyst initiations
07/13/21 H.C. Wainwright
Tempest Therapeutics initiated with a Buy at H.C. Wainwright
TPST Tempest Therapeutics
$3.83 /

+0.07 (+1.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.